Raymond James & Associates Verastem, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	SELL	$0.39 - $0.71 $487 - $887	-1,250 Reduced 2.72%	44,700 $18,000
Q4 2022 Feb 08, 2023	SELL	$0.33 - $10.44 $24,428 - $772,831	-74,026 Reduced 61.7%	45,950 $18,000
Q3 2022 Oct 25, 2022	SELL	$0.92 - $11.16 $1,457 - $17,677	-1,584 Reduced 1.3%	119,976 $102,000
Q2 2022 Aug 12, 2022	BUY	$1.02 - $1.83 $2,071 - $3,716	2,031 Added 1.7%	121,560 $141,000
Q1 2022 May 11, 2022	SELL	$1.06 - $2.1 $205,497 - $407,118	-193,866 Reduced 61.86%	119,529 $169,000
Q4 2021 Feb 08, 2022	SELL	$2.05 - $3.2 $33,929 - $52,963	-16,551 Reduced 5.02%	313,395 $642,000
Q3 2021 Nov 02, 2021	BUY	$2.54 - $4.07 $711,446 - $1.14 Million	280,097 Added 561.89%	329,946 $1.02 Million
Q2 2021 Aug 11, 2021	SELL	$2.57 - $4.85 $13,687 - $25,831	-5,326 Reduced 9.65%	49,849 $203,000
Q1 2021 May 14, 2021	BUY	$1.9 - $2.82 $2,090 - $3,102	1,100 Added 2.03%	55,175 $136,000
Q4 2020 Feb 12, 2021	BUY	$1.15 - $2.4 $172 - $360	150 Added 0.28%	54,075 $115,000
Q3 2020 Nov 04, 2020	SELL	$1.11 - $1.68 $327 - $495	-295 Reduced 0.54%	53,925 $65,000
Q2 2020 Jul 28, 2020	BUY	$1.69 - $4.2 $169 - $420	100 Added 0.18%	54,220 $93,000
Q1 2020 Apr 21, 2020	SELL	$1.26 - $3.38 $12,776 - $34,273	-10,140 Reduced 15.78%	54,120 $143,000
Q4 2019 Feb 12, 2020	BUY	$0.86 - $1.44 $1,936 - $3,242	2,252 Added 3.63%	64,260 $86,000
Q3 2019 Nov 07, 2019	BUY	$1.21 - $1.59 $159 - $209	132 Added 0.21%	62,008 $75,000
Q2 2019 Aug 06, 2019	BUY	$1.25 - $3.14 $16,212 - $40,725	12,970 Added 26.52%	61,876 $93,000
Q1 2019 May 06, 2019	BUY	$2.79 - $4.09 $18,135 - $26,585	6,500 Added 15.33%	48,906 $145,000
Q4 2018 Feb 11, 2019	SELL	$3.23 - $7.01 $15,504 - $33,648	-4,800 Reduced 10.17%	42,406 $142,000
Q3 2018 Nov 14, 2018	BUY	$6.86 - $9.97 $132,535 - $192,620	19,320 Added 69.28%	47,206 $342,000
Q2 2018 Aug 14, 2018	SELL	$2.88 - $8.67 $4,608 - $13,872	-1,600 Reduced 5.43%	27,886 $192,000
Q1 2018 May 14, 2018	SELL	$2.92 - $3.81 $78,256 - $102,108	-26,800 Reduced 47.61%	29,486 $88,000
Q4 2017 Feb 14, 2018	SELL	$2.99 - $4.85 $6,338 - $10,282	-2,120 Reduced 3.63%	56,286 $173,000
Q3 2017 Nov 13, 2017	BUY	$3.01 - $5.41 $137,746 - $247,577	45,763 Added 361.96%	58,406 $275,000
Q2 2017 Aug 14, 2017	BUY	N/A	12,643	12,643 $28,000

Others Institutions Holding VSTM

# of Institutions

Shares Held

297K

Call Options Held

Put Options Held

Telemetry Investments, L.L.C. New York, NY

225K
Shares

$897,750
0.14% of portfolio
Beaumont Financial Partners, LLC

48K
Shares

$191,520
0.0% of portfolio
Eaton Vance Management Boston, MA

20K
Shares

$79,800
0.0% of portfolio
American Portfolios Advisors Holbrook, NY

2.99K
Shares

$11,910
0.0% of portfolio
Brewin Dolphin Wealth Management LTD Conskleagh, Dublin, L2

1.07K
Shares

$4,285
0.0% of portfolio

View Full List

About Verastem, Inc.

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $838M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

More about VSTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account